Suggested remit: To appraise the clinical and cost effectiveness of cabotegravir and rilpivirine within its proposed marketing authorisation for treating adults with HIV-1.
 
Status In progress
Process STA 2018
ID number 3766

Provisional Schedule

Expected publication 20 October 2021

Project Team

Project lead Gavin Kenny

Email enquiries

Consultees

Companies sponsors ViiV Healthcare (cabotegravir and rilpivirine)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups National AIDS Trust
  UK-CAB
Professional groups British HIV Association
  Royal College of Pathologists
  Royal College of Physicians

Commentators

Comparator companies AbbVie (lopinavir, ritonavir)
  Accord (atazanavir, darunavir, efavirenz, emtricitabine, lamivudine, lopinavir, nevirapine, ritonavir, tenofovir) (confidentiality agreement not signed, not participating)
  Amneal Pharma (abacavir, lamivudine) (confidentiality agreement not signed, not participating)
  Aurobindo Pharma (efavirenz, lamivudine, nevirapine, tenofovir, zidovudine) (confidentiality agreement not signed, not participating)
  BMS (atazanavir, cobicistat, efavirenz) (confidentiality agreement not signed, not participating)
  Boehringer Ingelheim (nevirapine, tipranavir) (confidentiality agreement not signed, not participating)
  Bristol- Myers Squibb Pharmaceuticals limited (atazanavir, cobicistat, efavirenz, nevirapine) (confidentiality agreement not signed, not participating)
  Cipla (lamivudine, tenofovir) (confidentiality agreement not signed, not participating)
  Dr Reddy’s Laboratories (abacavir, atazanavir, darunavir, efavirenz, emtricitabine, lamivudine, nevirapine, tenofovir) (confidentiality agreement not signed, not participating)
  Gilead (bictegravir, cobicistat, efavirenz, elvitegravir, emtricitabine, rilpivirine, tenofovir) (confidentiality agreement not signed, not participating)
  GlaxoSmithKline (lamivudine) (confidentiality agreement not signed, not participating)
  Glenmark Pharmaceuticals (abacavir, emtricitabine, lamivudine, tenofovir) (confidentiality agreement not signed, not participating)
  Janssen (cobicistat, darunavir, emtricitabine, etravirine, rilpivirine, tenofovir)
  Lupin (abacavir, emtricitabine, lamivudine, tenofovir) (confidentiality agreement not signed, not participating)
  Mylan (abacavir, atazanavir, darunavir, efavirenz, emtricitabine, lamivudine, lopinavir, nevirapine, ritonavir, tenofovir, zidovudine) (confidentiality agreement not signed, not participating)
  MSD (doravirine, lamivudine, raltegravir, tenofovir) (confidentiality agreement not signed, not participating)
  Roche (enfuvirtide) (confidentiality agreement not signed, not participating)
  Sandoz (atazanavir, efavirenz, emtricitabine, tenofovir) (confidentiality agreement not signed, not participating)
  Sun Pharma (abacavir, lamivudine) (confidentiality agreement not signed, not participating)
  ViiV Healthcare (abacavir, dolutegravir, fosamprenavir, lamivudine, rilpivirine, zidovudine) (confidentiality agreement not signed, not participating)
  Wockhardt (nevirapine) (confidentiality agreement not signed, not participating)
  Zentiva (abacavir, atazanavir, darunavir, efavirenz, emtricitabine, lamivudine, tenofovir (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee

Timeline

Key events during the development of the guidance:

Date Update
01 December 2020 Invitation to participate
27 November 2020 In progress
03 August 2020 (10:00) Scoping workshop
17 June 2020 - 15 July 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance